Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
Peripheral Nervous System: Ganglia and Nerves01:24

Peripheral Nervous System: Ganglia and Nerves

The Peripheral Nervous System (PNS) is a crucial component of the body's neural network, extending beyond the central nervous system (CNS) to bridge the gap between the CNS and the external environment. It encompasses nerves, ganglia, and sensory receptors.
Nerves
The nerve is a bundle of axons that serves as the communication highway in the PNS. Each nerve is ensheathed in a protective layer of connective tissue called the epineurium. This outermost layer safeguards the nerve and supports the...
Glial Cells01:04

Glial Cells

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration.

Neuro-oncology·2026
Same author

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Neuro-oncology advances·2026
Same author

Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.

Cancer cell·2026
Same author

Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphoma.

Leukemia research reports·2026
Same author

Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma.

JCI insight·2026
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Primary central nervous system lymphoma.

Stephane Doucet1, Priya Kumthekar, Jeffrey Raizer

  • 1Department of Medicine, Division of Hematology-Oncology, Northwestern University, Feinberg School of Medicine, 676 North St. Clair, suite 850, Chicago, IL 60611, USA. stephane.doucet@northwestern.edu

Current Treatment Options in Oncology
|March 5, 2013
PubMed
Summary
This summary is machine-generated.

Primary central nervous system lymphoma (PCNSL) treatment is evolving. Research explores surgical resection, methotrexate-based chemotherapy, and radiotherapy, balancing efficacy with neurocognitive effects for potentially curable brain tumors.

Related Experiment Videos

Last Updated: May 13, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Neuro-oncology
  • Clinical research in brain tumors

Background:

  • Primary central nervous system lymphoma (PCNSL) incidence has risen, increasing research into optimal treatments.
  • PCNSL diagnosis traditionally relies on biopsy, but recent data suggest surgical resection may improve outcomes.

Purpose of the Study:

  • To review current and emerging treatment strategies for PCNSL.
  • To discuss the evolving role of surgery, chemotherapy, and radiotherapy in PCNSL management.
  • To highlight the importance of balancing treatment efficacy with neurocognitive toxicity.

Main Methods:

  • Review of recent clinical research and data on PCNSL treatment.
  • Analysis of chemotherapy regimens, including high-dose methotrexate and R-MVP.
  • Evaluation of the role and controversy surrounding whole brain radiotherapy (WBRT).

Main Results:

  • High-dose methotrexate-based chemotherapy can lead to disease cure.
  • Surgical resection may offer advantages in progression-free survival (PFS) and overall survival (OS).
  • Novel regimens like R-MVP followed by low-dose WBRT show promising disease control with reduced neurotoxicity.

Conclusions:

  • PCNSL is a potentially curable brain tumor requiring careful treatment strategy.
  • Balancing treatment effectiveness against long-term neurocognitive effects is critical for patient outcomes.
  • Ongoing research and clinical trials are refining PCNSL treatment protocols.